TMCnet News

Coave Therapeutics to Present at Upcoming Conferences
[March 27, 2024]

Coave Therapeutics to Present at Upcoming Conferences


Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences:

  • Cell & Gene Meeting on the Med – April 9-11 ; Rome, Italy
    Company Presentation by CEO Rodolphe Clerval on April 10 at 13.45 CET
  • LSX World Congress – April 29-30 ; London, UK
    CEO Rodolphe Clerval attending and available for investor meetings
  • BioEquity Europe – May 12-24 ; San Sebastián, Spain
    Company Presentation by CEO Rodolphe Clerval - Date/Time TBC
  • Gene Therapy Analytical Development Europe Summit - May 22-24 ; London, UK
    Presentation by COO Patricia Françon on May 24 at 10.00 BST

In addition, Coave’s scientific team will be present at the upcoming scientific, medical & regulatory conferences:

  • ARVO (Association for Research in Vision and Ophthalmology) - May 5-6 ; Seattle, WA, USASGCT (American Society of Gene and Cell Therapy) - May 7-11 ; Baltimore, MD, US



***

About Coave Therapeutics 


At Coave Therapeutics, we are leading the transition of genetic medicine from rare to prevalent conditions, starting with neurodegenerative and eye diseases. Our proprietary ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform introduces chemical modifications onto AAV capsids or Lipid Nanoparticles (LNPs) to overcome the limitations of current vectors on efficacy, safety, and manufacturability.  

With low doses and optimized routes of administration, our conjugated vectors have demonstrated markedly improved transduction and biodistribution in the central nervous system and the eye across different species. Our diverse pipeline of novel genetic medicines can potentially transform the lives of people afflicted by rare and prevalent neurodegenerative and ocular diseases – including genetically and non-genetically defined indications. 

Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit https://coavetx.com/ and follow us on LinkedIn

CONTACTS 

Coave Therapeutics 
Rodolphe Clerval, CEO 
[email protected]   

MEDiSTRAVA
Sylvie Berrebi, Leila Adlam, Mark Swallow 
[email protected]  
Tel: +44 (0)203 928 6900 


Primary Logo


[ Back To TMCnet.com's Homepage ]